

## **CEO Presentation For The Annual General Meeting 2025**

Welcome to the second Annual General Meeting of GODX Corporation (Aust) Ltd.

The last year has been a challenging and difficult one.

The group failed to generate sufficient sales to support its much needed corporate and technological development. The company was also deploying much of its attention and resources to completing critical developments as outlined at last year's AGM and that should bring much additional needed funding to the company and group.

With this funding, there are also plans and strategies to uplift the company to improve share value and share liquidity.

Our plans on delivering cutting-edge and proprietary technology in rapid diagnostics have not stopped although hampered due to limited resources but the company continues to be resilient to search for breakthroughs in this area.

We have secured at least 2 Memorandum of Understandings with synergistic partners to continue our development in this respect.

Our ongoing plan to leverage artificial intelligence and data analytics to empower individuals with personalized and effective healthcare solutions has not changed but has been put



on hold until our phase 1 of gathering sufficient data becomes more realized and completed.

At the central goal of our company, our intent to promote health and wellness for all of humanity remains steadfast.

We are pleased to announce that we have signed with a consortium comprising HKG Epitherapeutics (Canada/Hong Kong/China), Thailand Charter of Health (Thailand), Van Hanh Hospital (Vietnam), NSG (Singapore), International College of Surgeons (Singapore), International Centre for Men's Health (Singapore), Mint Definitive Wellness (Singapore), Paracelsus (Malaysia), TEI Studio (Singapore), Himawari Hotel Apartments (Cambodia), to pursue precision wellness and precision medicine in Asia Pacific. There is no requirement for GO-Dx to fund any or all of this.

Backed by an ecosystem of synergistic companies in the healthcare and wellness sectors, we continue to intend to transform the field of diagnostics and wellness that leverages the power of molecular pathology, microbiome, health data, and artificial intelligence. We therefore continue, consistent with our prospectus, to envision a future where every individual has access to personalized and accurate health information, enabling them to make informed decisions about their health and wellness.



Our unwavering goal is to develop innovative solutions that not only diagnose but also prevent diseases, providing better health outcomes for all of humanity.

On the front of going concern, specifically cash flow challenges, we advise cash receipts of ~AUD250K in the quarter since 1 October 2025. This is made possible due to an ongoing promotion based on an innovative marketing strategy.

Cody Blackhurst resigned as a director and company secretary in late October. We thank him for his contributions and wish him all the best for his future endeavors.

If elected during this AGM, we would welcome and Messrs. Stedwell, Pavlovski and Peh as our incoming directors.

During last year's AGM, I updated on a number of plans listed on the prospectus that require certain actions.

As an update for this AGM, I advise

1. There has been good development or commercialization of the RNA Mining/Mapping Platform and RNA Analytical Platform. Our signed MOU partners include Thailand Charter of Health, HKG Epitherapeutics, Van Hanh Hospital, KenPet Medical Pte Ltd, International Centre for Men's Health, EHA

Aesthetic Clinic, Paracelsus Wellness Sdn Bhd, TEI Studio and Himawari Hotel Apartment across 8 countries.

2. There has been planned development of an AI-Enabled Platform relating to RNA Mining/Mapping/Analytical Platform accordingly. Our signed Memorandum of Understanding with partners including the White Group and HKG Epitherapeutics.

We are working closely with Austrade too, to further develop our important networks within Australia to work with companies there to build AI-Enabled Platforms relating to RNA.

3. There has been some planned development or clinical validation of miRNA based biotechnologies for liquid biopsies for cancers. We are pleased to advise of signing of Memorandum of Understanding with partners including Thailand Charter of Health, HKG Epitherapeutics, Van Hanh Hospital and International Centre for Men's Health across 6 countries. The partners are exploring joint funding of activities at this time.

4. There has been good development of the intellectual property licensed to the Company to create novel inventions for the Company's use and exploitation. Our signed Memorandum of Understanding with partners including Thailand Charter of Health, HKG Epitherapeutics, Van Hanh Hospital, KenPet



Medical Pte Ltd, International Centre for Men's Health, EHA Aesthetic Clinic, Paracelsus Wellness Sdn Bhd, TEI Studio and Himawari Hotel Apartment across 8 countries.

With the explosion of newer and more powerful technological systems to generate genetic and other molecular health information, GO-Dx would be in an uniquely strong position to harness and capture the maximum values of valuable proprietary bio-data so as to predict pathological diseases for individuals that could be much faster and much reliable or real-time than current methods that are available to

the world now. The earlier capture of these valuable large volumes of bio-data, the more valuable the position of the company would be. Working with partners with strong AI capabilities, cloud management expertise and/or available CAP (College of American Pathologists) accredited laboratories, we could therefore capture these mentioned valuable large volumes of bio-data in the soonest possible time.

With these in mind, the board is optimistic that whatever has been outlined in the IPO prospectus, the company would be duly able to deliver those various milestones.